European regulators recommended against Teva Pharmaceutical's laquinimod, marring the Isreali company's odds of crossing the finish line with its once-promising multiple sclerosis treatment, a drug it hopes can dull the blow of the soon-to-go-generic Copaxone.
Regulators in Europe refused to give a favorable review to laquinimod, a potential successor treatment to Teva's multiple sclerosis drug Copaxone, which faces generic competition in May.
Teva and its multiple sclerosis partner Active Biotech rolled out some new top-line Phase III data on their troubled program for the oral multiple sclerosis drug laquinimod--still Teva's best shot at protecting the $4 billion franchise built up for Copaxone.
Don't be too surprised if Teva starts to make fresh headlines on the M&A side of the business. CEO Shlomo Yanai is telling reporters the company is acutely aware of just how badly it needs to
Teva's late-stage oral MS drug laquinimod flunked the second of three Phase III studies, the latest in a series of disappointments. Company officials say they can explain why the treatment failed to
With a multibillion-dollar market at stake, Teva shares were dented yesterday afternoon after word spread that its oral MS drug laquinimod cut relapses at a lower rate than standard injectable
Israel-based Teva Pharmaceutical announced today that the FDA has granted the Fast Track designation to laquinimod, its investigational treatment for relapsing-remitting multiple sclerosis (RRMS).